Commercial challenges and emerging trends in oral delivery of peptide and protein drugs: A review

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 2, Issue 3, 2011, Pages 778-790

  Sharma, Arvind ^a   Arora, Sandeep ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

Oral delivery; Protein peptides

Indexed keywords

2 HYDROXYETHYL METHACRYLATE; CHITOSAN; CYCLOSPORIN; ELCATONIN; GLYCEROL OLEATE; INSULIN; LIPOSOME; MACROGOL; MACROGOL 4000; MICROSPHERE; NANOPARTICLE; POLY(ISOBUTYL 2 CYANOACRYLATE); POLYGLACTIN; PROTEIN DERIVATIVE; SALCATONIN; SOLID LIPID NANOPARTICLE; STYRENE; TAUROCHOLIC ACID;

ARTICLE; CHEMICAL MODIFICATION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG TRANSPORT; ENCAPSULATION; ENZYME DEGRADATION; HUMAN; HYDROGEL; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; MICROEMULSION; OSTEOARTHRITIS; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TECHNOLOGY;

EID: 79960933671     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Saltzman WM. Biodegradable polymers; In: Drug delivery: Engineering principles for drug therapy. New York, Oxford University Press 2001; 334-350.
2. Lee HJ. Arch Pharm Res 2002; 25: 572-584.
3. Jen A, Merkle HP. Pharm Res 2001; 18: 1483-1488.
4. Degim IT, Celebi N. Curr Pharm Des 2007; 13: 99-117.
5. Frokjaer, S. and Otzen, D.D. Nat Rev Drug Discov 2005; 4: 298-306.
6. Torchilin VP and Lukyanov AN. Drug Discov Today 2003; 8:259-266.
7. Shah RB et al. Rev Ther Drug Carrier Syst 2002; 19: 135-169.
8. Mahato RI et al. Crit Rev Ther Drug Carrier Syst 2003; 20: 153-214.
9. Hamman JH et al. BioDrugs 2005; 19: 165-177.
10. Camenisch G et al. Eur J Pharm Sci 1998; 6: 317 324.
11. Rubas W et al. J Pharm Sci 1996; 85: 165-169.
12. Bendayan M et al. Diabetologia 1994; 37: 119-126.
13. Agarwal V and Khan MA. Pharm Technol 2001; 10: 76-90.
14. Bastian SEP et al. J Endocrinol 1999; 162: 361-369.
15. Morishita M et al. Biol Pharm Bull 1993; 16: 68-72.
16. Tozaki H et al. J Pharm Pharmacol 1998; 50: 913-920.
17. Ward PD et al. Pharm Sci Technol Today 2000; 3: 346-358.
18. Salamat-Miller N and Johnston TP. Int J Pharm 2005; 294: 201-216.
19. Salama NN et al. Adv Drug Deliv Rev 2006; 58: 15-28.
20. Fasano A. J Pharm Sci 1998; 87: 1351-1356.
21. Prego C et al. J Control Release 2005; 101: 151-162.
22. Bernkop-Schnurch A. Adv Drug Deliv Rev 2005; 57: 1569-1582.
23. Yen WC and Lee VHL. J Control Release 1995; 36: 25-37.
24. Gangwar S et al. Drug Discov Today 1997; 2: 148-155.
25. Mizuma T et al. Biochim Biophys Acta 2000; 1475: 90-98.
26. Hichens M. Drug Metab Rev 1983 14, 77-98.
27. Han HK and Amidon GL. AAPS PharmSci 2000; 2: E6.
28. Varma MVS et al. Pharmacol Res 2003; 48: 347-359.
29. Goto T et al. Pharm Res 2006; 23: 384-391.
30. (http://www.nobexcorp.com)
31. (http://www.gsk.com)
32. Van Der Lubben IM et al. J Drug Targeting 2001; 9: 39-47.
33. Lowman AM et al. J Pharm Sci 1993; 88: 933-937.
34. Desai MP et al. Pharm Res 1997; 14: 1568-1573.
35. Pan Y et al. Int J Pharm 2002; 249: 139-147.
36. Ma Z et al. Int J Pharm 2005; 293: 271-280.
37. Damge C et al. Diabetes 1988; 37: 246-251.
38. 17 Prego C et al. J Control Release 2005; 101: 151-162.
39. Kawashima Y et al. Pharm Dev Technol 2000; 5: 77-85.
40. Chung H et al. Diabetologia 2002; 45: 448-451.
41. Sakuma S et al. Int J Pharm 2002; 239: 185-195.
42. Saff ran M, Kumar GS, Neckers DC, Pena J, Jones RH, Fi{dotless}eld JB. Biochem Soc Trans 1990; 18(5):752-4.
43. Cheng CL, Gehrke SH, Ritschel WA. Methods Fi{dotless}nd Exp Clin Pharmacol 1994; 16(4):271-8.
44. Saff ran M, Kumar GS, Savariar C, Burnham JC, Williams F, Neckers DC. Science 1986; 233(4768):1081-4.
45. Brondsted H, Kopecek J. Biomaterials 1991; 12(6):584-92.
46. Brondsted H, Kopecek J. Pharm Res 1992; 9(12):1540-5.
47. Akala EO, Kopeckova P, Kopecek J. Biomaterials 1998; 19(11-12):1037-47.
48. Ghandehari H, Kopeckova P, Kopecek J. Biomaterials 1997; 18(12):861-72.
49. The DC Research Group. N Engl J Med 1993; 329: 977-986.
50. National Diabetes Data Group, Diabetes in America: Diabetes Data Compiled 1984. Bethesda Md. NIH. 85, 1985; 146X.
51. Engerman R, Bloodworth JM, Nelson S. Diabetes 1977; 26: 760-769.
52. Engerman R, Kern TS. Diabetes 1987; 36:8088812.
53. Wildmg R, Coupe AJ, Davis SS. Adv Drug Deliv Rev 1991; 7: 87-117.
54. Atchison JA, Grizzle WE, Pillion DJ. J Pharmacol Exp Ther 1989; 248: 567-572.
55. Manosroi KH Batter. Drug Dev Ind Pharm 1990; I6: 1521-1538.
56. Fukunaga M, Miller MM, Hostetler KY, Deftos LJ. Endocrinology I IS 1984; 757-61.
57. Jennifer's. Toxicology letter as 2001; 120:59-66.
58. Celies WE et al. Drug discovery today 2007; 12:674-81.
59. Bilsell P et al. J Immunology 2005; 174:3187-96.
60. Cindy H Dubin. Drug delivery technology march 2009; 8(3).
61. Marchant RE, Miller KM, Anderson JM. J Biomed Mater Res 1984; 18:1169-1174.
62. Sewell WR, Wiland J, Craver BN. Surg Gynecol Obstet 1955; 100:483-494.
63. Gourlay SJ, Rice RM, Hegyeli AF, Wade CWR, Dillon JG, Jaffe H, Kulkarni RK. J Biomed Mater Res 1978; 12:219-232.
64. Bronaugh RL, Maibach HI. Safety and efficacy of topical drugs and cosmetics. New York: Grune and Stratton. 51.
65. Foster GV. Safety and efficacy of topical drugs and cosmetics. New York: Grune and Stratton. 1982; 99.
66. Autian J. Toxicological aspects of implantable plastic used in medical and paramedical experiments. In: Williams DF, editor. Fundamental aspects of biocompatibility. Boca Raton, FL: CRC Press. 1983; 63.